HLAVNÍ TÉMA Role eozinofilů v patogenezi, diagnostice a léčbě bronchiálního astmatu 372 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék. 2023;69(6):365-372 / www.casopisvnitrnilekarstvi.cz 23. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper‑responsiveness, and the late asthmatic response. Lancet. 2000;356:2144-8. 24. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178:218-224. 25. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma. N Engl J Med. 2009;360:973-984. 26. Nair P, Pizzichini MMM, Kjarsgaard M, et al. Mepolizumab for Prednisone‑Dependent Asthma with Sputum Eosinophilia. New England Journal of Medicine. 2009;360:985-993. 27. Pavord ID, Haldar P, Bradding P, et al. Mepolizumab in refractory eosinophilic asthma. Thorax. 2010 65:370. 28. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. New England Journal of Medicine. 2014; 71:1198-1207. 29. Nair P, O‘Byrne PM. Measuring Eosinophils to Make Treatment Decisions in Asthma. Chest. 2016;150:485-7. 30. Mukherjee M, Nair P. Blood or sputum eosinophils to guide asthma therapy? Lancet Respir Med. 2015;3:824-825. 31. Kostikas K, Brindicci C, Patalano F. Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD. Curr Drug Targets. 2018;19:1882-1896. 32. Kroegel C, Liu MC, Hubbard WC, et al. Blood and bronchoalveolar eosinophils in allergic subjects after segmental antigen challenge: Surface phenotype, density heterogeneity, and prostanoid production. J Allergy Clin Immunol. 1994; 93:725-734. 33. Prin L, Capron M, Tonnel AB, et al. Heterogeneity of human peripheral blood eosinophils: Variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophilia. Int Arch Allergy Immunol. 1983; 72:336-346. 34. Kuo HP, Yu TR, Yu CT. Hypodense eosinophil number relates to clinical severity, airway hyperresponsiveness and response to inhaled corticosteroids in asthmatic subjects. European Respiratory Journal. 1994;7:1452-1459. 35. Abdala Valencia H, Loffredo LF, Misharin A V, et al. Phenotypic plasticity and targeting of Siglec‑FhighCD11clow eosinophils to the airway in a murine model of asthma. Allergy: European Journal of Allergy and Clinical Immunology 2016;71:267-271. 36. Matucci A, Nencini F, Maggiore G, et al. High proportion of inflammatory CD62L low eosinophils in blood and nasal polyps of severe asthma patients. Clinical & Experimental Allergy. 2023;53:78-87. 37. Kanda A, Yun Y, Bui D Van, et al. The multiple functions and subpopulations of eosinophils in tissues under steady‑state and pathological conditions. Allergology International. 2021;70:9-18. 38. Shah K, Ignacio A, McCoy KD, et al. The emerging roles of eosinophils in mucosal homeostasis. Mucosal Immunol. 2020;13:574-583. 39. Al‑Shaikhly T, Murphy RC, Parker A, et al. Location of eosinophils in the airway wall is critical for specific features of airway hyperresponsiveness and T2 inflammation in asthma. European Respiratory Journal. 2022;60:2101865. 40. Fukuda T, Dunnette SL, Reed CE, et al. Increased numbers of hypodense eosinophils in the blood of patients with bronchial asthma. American Review of Respiratory Disease. 1985;132:981-985. 41. Peters MS, Gleich GJ, Dunnette SL, et al. Ultrastructural study of eosinophils from patients with the hypereosinophilic syndrome: A morphological basis of hypodense eosinophils. Blood. 1988;71:780-785. 42. Januskevicius A, Jurkeviciute E, Janulaityte I, et al. Blood Eosinophils Subtypes and Their Survivability in Asthma Patients. Cells. 2020;9:1248. 43. Van Hulst G, Jorssen J, Jacobs N, et al. Anti‑IL5 mepolizumab minimally influences residual blood eosinophils in severe asthma. European Respiratory Journal. 2022;59:2100935. 44. Novosad J, Krčmová I, Souček O, et al. Subsets of Eosinophils in Asthma, a Challenge for Precise Treatment. Int J Mol Sci. 2023; 24: 5716. 45. Freeman CM, Curtis JL, Hastie AT. Finding the Right Biological: Eosinophil Subset Differences in Asthma and COPD. Am J Respir Crit Care Med. Epub ahead of print 13 June 2023. DOI: 10.1164/RCCM.202305-0811ED. 46. Cabrera López C, Sánchez Santos A, Lemes Castellano A, et al. Eosinophils Sub ‑Types in Asthmatic and COPD Patients. Am J Respir Crit Care Med. Epub ahead of print 18 April 2023. DOI: 10.1164/rccm.202301-0149OC. 47. Ijaz T, Pazdrak K, Kalita M, et al. Systems biology approaches to understanding Epithelial Mesenchymal Transition (EMT) in mucosal remodeling and signaling in asthma. World Allergy Organ J. 2014;7:13. 48. Denton E, Price DB, Tran TN, et al. Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry. Journal of Allergy and Clinical Immunology: In Practice 2021;9:2680-2688.e7. 49. Chen M, Shepard K, Yang M, et al. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate‑to‑severe asthma. Clinical and Experimental Allergy. 2021;51:546-555. 50. Corren J, Du E, Gubbi A, et al. Variability in Blood Eosinophil Counts in Patients with Eosinophilic Asthma. Journal of Allergy and Clinical Immunology: In Practice 2021; 9: 1224-1231.e9. 51. Kroes JA, Zielhuis SW, van Roon EN, et al. Prediction of response to biological treatment with monoclonal antibodies in severe asthma. Biochem Pharmacol. 2020;179:113978. 52. Rogliani P, Calzetta L, Matera MG, et al. Severe Asthma and Biological Therapy: When, Which, and for Whom. Pulm Ther. 2020;6:47-66. 53. Eger K, Kroes JA, ten Brinke A, et al. Long‑Term Therapy Response to Anti–IL-5 Biologics in Severe Asthma-A Real‑Life Evaluation. J Allergy Clin Immunol. Pract 2021;9:1194-1200. 54. McDowell PJ, Diver S, Yang F, et al. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. Lancet Respir Med. 2021;9:1174-1184. 55. Poznanski SM, Mukherjee M, Zhao N, et al. Asthma exacerbations on benralizumab are largely non‑eosinophilic. Allergy: European Journal of Allergy and Clinical Immunology. 2021;76:375-379. 56. Nair P, O‘Byrne PM. Medical algorithms: Approach to adult asthma exacerbations. Allergy. 2021;76:3556-3559. 57. Menzies‑Gow A, Bafadhel M, Busse WW, et al. An expert consensus framework for asthma remission as a treatment goal. Journal of Allergy and Clinical Immunology. 2020;145:75-65. 58. Menzies‑Gow A, Szefler SJ, Busse WW. The Relationship of Asthma Biologics to Remission for Asthma. Journal of Allergy and Clinical Immunology: In Practice. 2021;9:1090-1098. 59. Maglio A, Vitale C, Pelaia C, et al. Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real‑Life Study. Int J Mol Sci. 2023;24:2455. 60. Mengelers HJJ, Maikoe T, Hooibrink B, et al. Down modulation of L‑Selection expression on eosinophils recovered from bronchoalveolar lavage fluid after allergen provocation. Clinical and Experimental Allergy. 1993;23:196-204. Pro věrné čtenáře Součástí Vnitřního lékařství 6/2023 je navíc suppelementum Zaznělo na XXXI. výročním sjezdu České kardiologické společnosti. Najdete v něm přehledná shrnutí několika zajímavých bloků z jarního kongresu České kardiologické společnosti v Praze a Brně. Věříme, že pro vás připomenutí této významné internistické akce bude přínosné.
RkJQdWJsaXNoZXIy NDA4Mjc=